



Our 2021 Report

Janssen

£15,000 went towards research undertaken by UCL in order to reduce [delays to diagnosis of blood cancer](#). Another £30,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. £480 was received for attendance to an advisory board and £420 for a haematology summit meeting.

Gilead

£25,675 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. £9,824 went towards employability support for staff made redundant in restructure. £720 was received for attendance to an advisory board.

Pfizer

£63,500 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Novartis

£11,568 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. Another £53,889 supported our [Clinical Trials Support Service](#) and £600 for advisory board attendance.

Celgene

£11,563 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. Another £39,000 supported our [Clinical Trials Support Service](#).

Takeda

£11,563 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. Another £53,889 supported our [Clinical Trials Support Service](#).

Bristol Myers Squibb

£53,889 went towards our [Clinical Trials Support Service](#)



AbbVie

£11,563 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. £10,000 went towards research undertaken by UCL in order to reduce [delays to diagnosis of blood cancer](#). We received £150 for advisory board attendance and £450 for patient interviews.

Roche

£5,000 went towards patient information.

Jazz

£10,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Sanofi

£7,024 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Amgen

£10,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Incyte

£11,563 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic. Another £10,000 went towards our psychological support research.

Servier

£1,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

AstraZeneca

£11,563 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Kyowa Kirin

£5,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.



Autolus

£10,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

Chiesi

£1,000 went towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

GSK

£9,437 went towards our befriending service.

Astellas

£7,500 went towards our support services.